Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.03 USD | -0.33% |
|
+0.66% | -26.81% |
Business Summary
Number of employees: 20
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 30/05/12 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
Charles Ence
CMP | Compliance Officer | 64 | 28/07/19 |
John Hixon
PRN | Corporate Officer/Principal | - | 20/07/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 13/07/15 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
Fabiana Fedeli
BRD | Director/Board Member | 53 | 11/01/23 |
Director/Board Member | 61 | 18/12/19 | |
Paul Kelly
BRD | Director/Board Member | 65 | 11/11/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 30,174,202 | 27,748,959 ( 91.96 %) | 0 | 91.96 % |
Company contact information
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard 3rd floor
33134, Coral Gables
+786-629-1376
http://www.relmada.com![address Relmada Therapeutics, Inc.(RLMD)](https://cdn.zonebourse.com/static/address/73538250.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.81% | 91.43M | |
+15.19% | 121B | |
+19.91% | 114B | |
+18.81% | 23.61B | |
-19.80% | 20.43B | |
-15.64% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- RLMD Stock
- Company Relmada Therapeutics, Inc.